An artificial solution for adoptive immunotherapy

Trends in Biotechnology

Volumn 21, Issue 10, 2003, Pages 418-420

  Zemon, Harry ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CELLS; DISEASES; PROTEINS; TUMORS;

ADOPTIVE IMMUNOTHERAPY; INFECTIOUS DISEASES;

IMMUNOLOGY;

CD45 ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 2;

IMMUNE SYSTEM; MEDICINE;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CELL FUNCTION; CHEMICAL INTERACTION; CHIMERA; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; MELANOMA; METHODOLOGY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 1642373046     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2003.08.005     Document Type: Short Survey

References (23)

1. Melief C.J., Kast W.M. T cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145:1995;167-177.
2. Riddell S.R., Greenberg P.D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13:1995;545-586.
3. Oelke M., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9:2003;619-625.
4. Riddell S.R., et al. Selective reconstitution of CD81 cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant. 14:(Suppl 4):1994;S78-S84.
5. Walter E.A., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. New Engl. J. Med. 333:1995;1038-1044.
6. Heslop H.E., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2:1996;551-555.
7. Heslop H.E., et al. Donor T cells to treat EBV-associated lymphoma. New Engl. J. Med. 331:1994;679-680.
8. Brodie S.J., et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:1999;34-41.
9. Brodie S.J., et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest. 105:2000;1407-1417.
10. Rosenberg S.A., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl. J. Med. 319:1988;1676-1680.
11. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
12. Maus M.V., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 20:2002;143-148.
13. Greten T.F., et al. Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J. Immunol. Methods. 271:2002;125-135.
14. June C.H., et al. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321-331.
15. Jenkins M.K., Johnson J.G. Molecules involved in T cell costimulation. Curr. Opin. Immunol. 5:1993;361-367.
16. Baxevanis C.N., et al. Tumor-specific CD41 T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 164:2000;3902-3912.
17. Marzo A.L., et al. Tumor-specific CD41 T cells have a major 'posT licensing' role in CTL mediated anti-tumor immunity. J. Immunol. 165:2000;6047-6055.
18. Pardoll D.M., Topalian S.L. The role of CD41 T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:1998;588-594.
19. Topalian S.L. MHC class II restricted tumor antigens and the role of CD41 T cells in cancer immunotherapy. Curr. Opin. Immunol. 6:1994;741-745.
20. Lin K.Y., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
21. Meidenbauer N., et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2003;2161-2169.
22. + T-cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99:2002;16168-16173.
23. Yee C. Adoptive T cell therapy - immune monitoring and MHC multimers. Clin. Immunol. 106:2003;5-9.